Pharmacokinetics and pharmacodynamics of azithromycin in severe malaria bacterial co-infection in African children (TABS-PKPD): a protocol for a Phase II randomised controlled trial

Olupot-Olupot, Peter, Okiror, William, Mnjalla, Hellen, Muhindo, Rita, Uyoga, Sophie, Mpoya, Ayub, Williams, Thomas N, terHeine, Rob, Burger, David M, Urban, Britta ORCID: https://orcid.org/0000-0002-4197-8393, Connon, Roisin, George, Elizabeth C, Gibb, Diana M, Walker, A Sarah and Maitland, Kathryn (2023) 'Pharmacokinetics and pharmacodynamics of azithromycin in severe malaria bacterial co-infection in African children (TABS-PKPD): a protocol for a Phase II randomised controlled trial'. Wellcome Open Research, Vol 6, e161.

Preview

Text 191acc76-bbb4-44ad-b0dc-0f4912106a7d_16968_-_kathryn_maitland_v2_(1).pdf - Published Version Available under License Creative Commons Attribution. Download (993kB) | Preview

Abstract

African children with severe malaria are susceptible to Gram-negative bacterial co-infection, largely non-typhoidal Salmonellae, leading to a substantially higher rates of in-hospital and post-discharge mortality than those without bacteraemia. Current evidence for treating co-infection is lacking, and there is no consensus on the dosage or length of treatment required. We therefore aimed to establish the appropriate dose of oral dispersible azithromycin as an antimicrobial treatment for children with severe malaria and to investigate whether antibiotics can be targeted to those at greatest risk of bacterial co-infection using clinical criteria alone or in combination with rapid diagnostic biomarker tests. A Phase I/II open-label trial comparing three doses of azithromycin: 10, 15 and 20 mg/kg spanning the lowest to highest mg/kg doses previously demonstrated to be equally effective as parenteral treatment for other salmonellae infection. Children with the highest risk of bacterial infection will receive five days of azithromycin and followed for 90 days. We will generate relevant pharmacokinetic data by sparse sampling during dosing intervals. We will use population pharmacokinetic modelling to determine the optimal azithromycin dose in severe malaria and investigate azithromycin exposure to change in C-reactive protein, a putative marker of sepsis at 72 hours, and microbiological cure (seven-day), alone and as a composite with seven-day survival. We will also evaluate whether a combination of clinical, point-of-care diagnostic tests, and/or biomarkers can accurately identify the sub-group of severe malaria with culture-proven bacteraemia by comparison with a control cohort of children hospitalized with severe malaria at low risk of bacterial co-infection. : We plan to study azithromycin because of its favourable microbiological spectrum, its inherent antimalarial and immunomodulatory properties and dosing and safety profile. This study will generate new data to inform the design and sample size for definitive Phase III trial evaluation. ISRCTN49726849 (27 October 2017).

Item Type:	Article
Subjects:	WB Practice of Medicine > Therapeutics > WB 330 Drug therapy WC Communicable Diseases > Infection. Bacterial Infections > Bacterial Infections > WC 200 Bacterial infections (General or not elsewhere classified) WC Communicable Diseases > Tropical and Parasitic Diseases > WC 750 Malaria WS Pediatrics > Diseases of Children and Adolescents > General Diseases > WS 200 General works
Faculty: Department:	Biological Sciences > Department of Tropical Disease Biology
Digital Object Identifer (DOI):	https://doi.org/10.12688/wellcomeopenres.16968.2
SWORD Depositor:	JISC Pubrouter
Depositing User:	JISC Pubrouter
Date Deposited:	14 Aug 2023 08:54
Last Modified:	14 Aug 2023 08:54
URI:	https://archive.lstmed.ac.uk/id/eprint/22955

Statistics

View details

Actions (login required)

Edit Item